Evidence map›Paper›PMID 40751531›Full record

ArticleArchives of Iranian medicine2025

Clinicopathological Perspectives of Liver Mass Biopsies: A Single Center Experience of 406 Cases.

Ömer Atmış, Hanife Seda Mavili, Fatma Seher Pehlivan, Ahmet Burak Ağaoğlu, Atike Pınar Erdoğan, Mustafa Faraşat, Semin Ayhan

Abstract read
In one paragraph

Article in Archives of Iranian medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Multidimensional roles and clinical significance of GATA3 in breast cancer.Frontiers in cell and developmental biology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ömer AtmışDepartment of Pathology, Faculty of Medicine, Manisa Celal Bayar University, Manisa, Turkey.ORCID 0000-0003-4789-0875
Hanife Seda MaviliDepartment of Pathology, Faculty of Medicine, Manisa Celal Bayar University, Manisa, Turkey.ORCID 0000-0003-3741-8489
Fatma Seher PehlivanDepartment of Pathology, Faculty of Medicine, Manisa Celal Bayar University, Manisa, Turkey.ORCID 0000-0002-7702-855X
Ahmet Burak AğaoğluDepartment of Medical Oncology, Faculty of Medicine, Manisa Celal Bayar University, Manisa, Turkey.ORCID 0000-0001-5528-7852
Atike Pınar ErdoğanDepartment of Medical Oncology, Faculty of Medicine, Manisa Celal Bayar University, Manisa, Turkey.ORCID 0000-0003-4859-7574
Mustafa FaraşatDepartment of Radiology, Faculty of Medicine, Manisa Celal Bayar University, Manisa, Turkey.ORCID 0000-0002-8019-1235
Semin AyhanDepartment of Pathology, Faculty of Medicine, Manisa Celal Bayar University, Manisa, Turkey.ORCID 0000-0002-8546-0705

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe increasing use of imaging techniques has led to a rise in the detection of liver masses, making it crucial to accurately diagnose their nature. While advances in radiology have reduced the need for liver biopsy in hepatocellular carcinoma (HCC), biopsy remains essential fo r diagnosing various liver lesions, including metastatic tumors. This study aims to evaluate the diagnostic role of liver core needle biopsies, with a particular focus on identifying the primary tumor in cases of liver metastases with an unknown primary.

methodsWe reviewed a total of 406 liver core needle biopsies performed for liver masses between 2017 and 2022. Clinical, radiological, histopathological and immunohistochemical (IHC) data for primary and metastatic tumors were evaluated.

resultsOf the 406 liver biopsy cases, a significant portion were diagnosed as metastatic lesions, with common primary sites identified as gastrointestinal (GI), lung, and breast cancers. IHC markers showed varying positivity rates across different tumor types, with GATA-3, CDX2, and TTF1 proving particularly useful in distinguishing the tumor origin. While some markers were highly specific, others exhibited variable expression, highlighting the complexity of diagnosing metastatic tumors with unknown primaries.

conclusionLiver biopsy remains a crucial diagnostic tool in identification of primary and metastatic liver tumors, especially when the primary site is unknown. IHC analysis enhances the accuracy of diagnosis, though it should be used in conjunction with clinical and radiological data. This study underscores the importance of a multidisciplinary approach in managing liver masses, with further research needed to optimize diagnostic strategies and improve patient outcomes.

Indexed as

Carcinoma, HepatocellularLiverLiver NeoplasmsNeoplasms, Unknown PrimaryAdultAgedAged, 80 and overBiomarkers, TumorBiopsy, Large-Core NeedleBreast NeoplasmsFemaleHumansImmunohistochemistryLung NeoplasmsMaleMiddle AgedBiomarkers, TumorCholangiocarcinomaHepatocellular carcinomaImmunohistochemistryLiver mass biopsyLiver metastasis

Identifiers

PMID40751531
PMCPMC12305414

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.